STOCK TITAN

RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

Welcome to our dedicated page for RELIEF THERAPEUTICS HLDG news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on RELIEF THERAPEUTICS HLDG stock.

RELIEF THERAPEUTICS Holding SA, traded as RLFTF, is a biopharmaceutical company dedicated to providing innovative treatment options for select specialty, unmet, and rare diseases. The company focuses on advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit patients. Relief Therapeutics offers a diversified portfolio of marketed products, proprietary platform technologies, and a targeted clinical development pipeline. With a mission to provide therapeutic relief to those suffering from rare diseases, Relief Therapeutics is led by an experienced team of industry leaders. Headquartered in Geneva, the company is listed on the SIX Swiss Exchange and quoted on the OTCQB.

Rhea-AI Summary

Relief Therapeutics Holding SA has announced the appointment of Tracy Truong and Kelli Powell as Regional Clinical Specialists for the West and Northeast Regions, effective May 23, 2022. Both specialists bring significant experience in pharmaceutical sales, particularly in rare diseases, having worked for top companies like Alexion and NPS Pharmaceuticals. Their expertise will support the anticipated rollout of PKU GOLIKE and the potential launch of ACER-001 for Urea Cycle Disorders, with a crucial PDUFA date set for June 5, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics Holding SA has submitted Amendment No. 2 to its Registration Statement on Form 20-F to the U.S. SEC, aiming to transition its Level 1 American Depositary Receipt (ADR) program to a Level 2 ADR program. This is part of Relief's goal to list its ADRs on the NASDAQ Stock Market. The effectiveness of the Registration Statement and the subsequent NASDAQ listing remain uncertain. Notably, there are no proceeds from this filing as it does not involve a securities offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics announced its participation in two significant conferences in May 2022, including Bio€quity Europe and the H.C. Wainwright Global Investment Conference. CFO Jack Weinstein will present at both events, with presentations scheduled for May 17 in Milan and May 24 virtually. Relief is advancing its drug candidate, RLF-100 (aviptadil), for treating respiratory issues linked to COVID-19, while also collaborating on ACER-001 for metabolic disorders. The company's ongoing efforts reflect a commitment to addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
conferences
Rhea-AI Summary

Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) presented data on ACER-001 (sodium phenylbutyrate) at the GMDI Conference on May 5, 2022. The studies demonstrated that ACER-001 is bioequivalent to BUPHENYL under fasting and fed conditions, with no major safety concerns. The companies anticipate a decision from the FDA regarding the new drug application on June 5, 2022, and plan to submit a marketing application in the EU later this year. ACER-001 aims to address unmet needs in Urea Cycle Disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics Holding SA has announced its Annual General Meeting (AGM) scheduled for May 31, 2022, which will be held without shareholder presence due to COVID-19. The Board recommends approval of key items including the Annual Report for 2021, carrying forward a loss of CHF 29,553,450, increasing authorized share capital to CHF 22 million, and approving compensation for the Board and Executive Committee totaling CHF 7.5 million. The meeting will also include re-elections for Board members and auditors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics announced that its subsidiary, APR Applied Pharma Research, received a Notice of Allowance for Patent Application No. 15/303,121 from the U.S. Patent and Trademark Office. This patent covers PKU GOLIKE(R) formulations, enhancing dietary management for patients with phenylketonuria (PKU). The patent, valid until at least September 27, 2036, strengthens Relief's intellectual property and supports plans for a U.S. launch of PKU GOLIKE(R) in mid-2022, pending approval. The formulation is designed to mimic natural protein absorption while masking unpleasant flavors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Relief Therapeutics announces the appointment of Drew Cronin-Fine as Executive Director, Head of U.S. Marketing, effective May 3, 2022. This strategic hire aims to bolster the U.S. commercial team ahead of the anticipated product rollouts for PKU GOLIKE and ACER-001, with a PDUFA date set for June 5, 2022. Cronin-Fine brings extensive experience from her previous roles at Intercept Pharmaceuticals and Cubist Pharmaceuticals, focusing on rare diseases and digital marketing strategies. This move is expected to enhance Relief's capabilities in the evolving rare disease market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Relief Therapeutics announced that its partner, NRx Pharmaceuticals, has filed for Breakthrough Therapy Designation with the FDA for aviptadil in patients with Critical COVID-19 who were also treated with remdesivir. The request is based on a post-hoc analysis of around 750 patients and aims to address ongoing respiratory failure. Relief's ongoing collaborations also include a licensing agreement with Acer Therapeutics for another treatment. The PDUFA date for Acer's new drug application is set for June 5, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
Rhea-AI Summary

Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) presented data on ACER-001 at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting held from April 10-13, 2022. The studies demonstrated that taste-masked sodium phenylbutyrate (ACER-001) is bioequivalent to BUPHENYL® under both fasting and fed conditions, with similar safety profiles. The FDA's PDUFA date for ACER-001 is set for June 5, 2022, with potential benefits for patients with urea cycle disorders (UCDs). The findings highlight ACER-001 as a promising alternative therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
Rhea-AI Summary

RELIEF THERAPEUTICS Holding SA announced that the Swiss Patent Office has granted a patent for Vasoactive Intestinal Peptide (VIP) for treating drug-induced pneumonitis, enhancing the intellectual property for RLF-100 (aviptadil) until at least 2039. This patent covers treatment for checkpoint inhibitor-related pneumonitis and methotrexate-induced pneumonitis. Clinical studies, including the NIH-sponsored ACTIVE-3b/TESICO study, are ongoing. Aviptadil's inhalation method shows promising results, offering rapid and targeted treatment, which can improve patient outcomes significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of RELIEF THERAPEUTICS HLDG (RLFTF)?

The current stock price of RELIEF THERAPEUTICS HLDG (RLFTF) is $4.31 as of January 13, 2025.

What is the market cap of RELIEF THERAPEUTICS HLDG (RLFTF)?

The market cap of RELIEF THERAPEUTICS HLDG (RLFTF) is approximately 58.6M.

What does RELIEF THERAPEUTICS Holding SA do?

RELIEF THERAPEUTICS Holding SA is a biopharmaceutical company dedicated to providing innovative treatment options for select specialty, unmet, and rare diseases.

Where is RELIEF THERAPEUTICS Holding SA headquartered?

RELIEF THERAPEUTICS Holding SA is headquartered in Geneva.

On which stock exchanges is RELIEF THERAPEUTICS Holding SA listed?

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.

What is the mission of RELIEF THERAPEUTICS Holding SA?

The mission of RELIEF THERAPEUTICS Holding SA is to provide therapeutic relief to those suffering from rare diseases.

Who leads RELIEF THERAPEUTICS Holding SA?

RELIEF THERAPEUTICS Holding SA is led by an international team of well-established, experienced biopharma industry leaders with extensive research, development, and rare disease expertise.

What are the core therapeutic areas of focus for RELIEF THERAPEUTICS Holding SA?

RELIEF THERAPEUTICS Holding SA focuses on rare skin diseases, rare metabolic disorders, and rare respiratory diseases.

How can I learn more about RELIEF THERAPEUTICS Holding SA?

For more information about RELIEF THERAPEUTICS Holding SA, please visit their website at www.relieftherapeutics.com or follow them on LinkedIn.
RELIEF THERAPEUTICS HLDG

OTC:RLFTF

RLFTF Rankings

RLFTF Stock Data

58.65M
9.65M
23.15%
Biotechnology
Healthcare
Link
United States of America
Geneva